Amin Sharifan, PharmD

Dobrescu, A.I.; Pinte, L.; Sharifan, A.; Gadinger, A.; Moser, I.; Cooper, C.; Gartlehner, G. (2026). Effectiveness, Comparative Effectiveness, and Harms of COVID-19 Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-05044.

GBD 2021 AEMT Collaborators; Sharifan, A. (2026). Global burden of adverse effects of medical treatment from 1990 to 2021: a Global Burden of Disease Study 2021. Korean J Intern Med, 41(2): 350-366

GBD 2023 Breast Cancer Collaborators; Sharifan, A. (2026). Global, regional, and national burden of breast cancer among females, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Oncology, Volume 27, Issue 3: 302-326

GBD 2023 IHD & Dietary Risk Factors Collaborators; Sharifan, A. (2026). Global, regional and national burden of ischemic heart disease attributable to suboptimal diet, 1990–2023: a Global Burden of Disease study. Nature Medicine, 32: 1454-1478

GBD 2023 Iran Collaborators; Sharifan, A.; et. al. (2026). Burden of 292 causes of death and life expectancy decomposition in Iran, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Global Health, 14(5): e734-e748

GBD 2023 Maternal Mortality Collaborators; Sharifan, A. (2026). Global, regional, and national levels and trends in maternal mortality, progress towards the Sustainable Development Goals, and mortality from COVID-19 infection in pregnant women, 1990–2023: a systematic analysis for the Global Burden of Disease Study 23. Lancet Obstet Gynaecol Womens Health, 2 (5): e375-e424

GBD 2023 Meningitis & Antimicrobial Resistance Collaborators; Sharifan, A. (2026). Global, regional, and national burden of meningitis, its risk factors, and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet Neurology, 25(5): P451-468

GBD 2023 Mental Disorder Collaborators; Sharifan, A.; et. al. (2026). Updated trends in the global prevalence and burden of mental disorders, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet, 407: 2040-64

Kang, J.; et. al.; Sharifan, A. (2026). Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study. Nature Medicine, 32: 527-544

Moser, T.K.; Dobrescu, A.I.; Sommer, I.; Goeschl, S.; Sharifan, A.; Ledinger, D.; Klerings, I.; Gartlehner, G. (2026). Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-05536.

Oh, J.; et. al.; Sharifan, A. (2026). Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study. Nature Medicine, 32: 197-223

Sharifan, A. (2026). Misrepresentation of nonsignificant results: reporting pitfalls in urology randomised trials. BJU International, https://doi.org/10.1111/bju.70139: https://doi.org/10.1111/bju.70139

Sharifan, A.; Dobrescu, A.I.; Klerings, I.; Gartlehner, G. (2026). Update Alert 4: Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-26-00504.

Sharifan, A.; Fonarow, G.C. (2026). Statistical Misinterpretation of Nonsignificant Results in Diabetes Randomised Clinical Trials. Diabetes Metabolism Research and Reviews, 4: e70179

Sharifan, A.; Gadinger, A.; Cooper, C.; Braun, A. (2026). Vitrectomy After Cataract Surgery as a Patient Safety Indicator: A Rapid Review to Support Benchmarking Within the Austrian Inpatient Quality Indicators Framework. Journal of Patient Safety, 10.1097: 1-11

Sharifan, A.; Harrod, C.; Dobrescu, A.; Gartlehner, G. (2026). Reverse fragility index shows high fragility in Cochrane meta-analyses with P values between 0.05 and 0.20: a meta-epidemiological study. Journal of Clinical Epidemiology, 195: https://doi.org/10.1016/j.jclinepi.2026.112285

Sharifan, A.; Harrod, C.; Dobrescu, A.; Gartlehner, G. (2026). Evaluating evidential strength of statistically nonsignificant meta-analyses with likelihood ratios: a meta-epidemiological study. Journal of Clinical Epidemiology, 195: https://doi.org/10.1016/j.jclinepi.2026.112297

Sommer, I. Dobrescu, A. Gadinger, A. Sharifan, A. Pinte, L. Fangmeyer, M. Klerings, I. Gartlehner, G. (2026). Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3). Annals of Internal Medicine, Online ahead of print: 10.7326/ANNALS-25-03691.

Ryan-Vig, S.; Sharifan, A. (2026). For people undergoing first-line treatment for advanced pancreatic cancer, how do gemcitabine-containing dual chemotherapy regimens compare with gemcitabine alone? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4689: https://doi.org/10.1002/cca.4689

Ryan-Vig, S.; Sharifan, A. (2026). What are the benefits and harms of different interventions for people interested in quitting nicotine-containing vapes? Cochrane Clinical Answers, https://doi.org/10.1002/cca.4746: https://doi.org/10.1002/cca.4746